
The flexible dosing schedule has been approved for patients with skin, lung and cervical cancer

Results show trevogrumab prevents lean mass and muscle loss during GLP-1 weight loss

Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history

The results from a global phase 3 trial show the longest survival data ever reported in this setting

Globally, around 150 to 200 out of every million people have myasthenia gravis

Regeneron will pay Parabilis $125m upfront, with up to $2.2bn in potential milestone payments and royalties

This is the first and only perioperative immunotherapy approved to treat early gastric cancers

Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

Phase 3 trial results showed the drug significantly improved disease-free survival

Lung cancer is the leading cause of cancer-related deaths worldwide

Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year